BIOCRYST PHARMACEUTICALS INC: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp has disclosed a stake exceeding 5% in BioCryst Pharmaceuticals Inc. via a Schedule 13G filing with the SEC, accession number 0000093751-26-000622. The filing signals that State Street's position has crossed the threshold requiring public disclosure under U.S. securities rules. BioCryst, which develops oral small-molecule drugs for rare diseases, now counts the major institutional investor among its significant holders. The exact share count and percentage were not specified in the filing summary. Investors will watch for further 13G amendments or 13D filings that could indicate a more active stance.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
State Street Corp, BioCryst Pharmaceuticals Inc